Cerevel Therapeutics, Jazz Pharmaceuticals, and more Pharma Companies among Worst Performers in Today’s Market

306

In today’s stock market, the pharma company with the worst stock price performance is Cerevel Therapeutics. The data from the stock market listings shows that Cerevel Therapeutics’ share prices have plummeted by 4.40%. This has pulled the stock price of the US-based pharma company down to $32.14 per share. Cerevel Therapeutics’ global pharma ranking is 98, after achieving a market valuation worth $4.73 billion.

The next pharma company making into the list after Cerevel Therapeutics is Jazz Pharmaceuticals. The data from the stock market listings shows that Jazz Pharmaceuticals’ share prices have plummeted by 4.04%. This has pulled the stock price of the Ireland-based pharma company down to $124.09 per share. Jazz Pharmaceuticals’ global pharma ranking is 70, after achieving a market valuation worth $7.62 billion.

The next pharma company made into the list after Jazz Pharmaceuticals is Beam Therapeutics. The data from the stock market listings shows that Beam Therapeutics’ share prices have plummeted by 3.93%. This has pulled the stock price of the US-based pharma company down to $78.69 per share. Beam Therapeutics’ global pharma ranking is 90, after achieving a market valuation worth $5.36 billion.

The next pharma company making into the list after Beam Therapeutics is Fate Therapeutics. The data from the stock market listings shows that Fate Therapeutics’ share prices have plummeted by 3.49%. This has pulled the stock price of the US-based pharma company down to $52.52 per share. Fate Therapeutics’ global pharma ranking is 93, after achieving a market valuation worth $5.01 billion.

The next pharma company making into the list after Fate Therapeutics is Lundbeck. The data from the stock market listings shows that Lundbeck’s share prices have plummeted by 3.44%. This has pulled the stock price of the Denmark-based pharma company down to $24.90 per share. Lundbeck’s global pharma ranking is 95, after achieving a market valuation worth $4.99 billion.

The next pharma company making into the list after Lundbeck is Bayer. The data from the stock market listings shows that Bayer’s share prices have plummeted by 3.31%. This has pulled the stock price of the Germany-based pharma company down to $51.48 per share. Bayer’s global pharma ranking is 27, after achieving a market valuation worth $50.70 billion.

The next pharma company making into the list after Bayer is Bausch Health. The data from the stock market listings shows that Bausch Health’s share prices have plummeted by 3.29%. This has pulled the stock price of the Canada-based pharma company down to $25.25 per share. Bausch Health’s global pharma ranking is 60, after achieving a market valuation worth $9.07 billion.

Several other companies such as Chugai Pharmaceutical, Hansoh Pharma, Sumitomo Dainippon Pharma, and more have also experienced a great plummet in their stock prices in today’s market.